RecruitingPhase 2NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Volrustomig(biological)
Enrollment: 257 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2028

Study locations (30)

Research Site, Los Angeles, California, United States
Research Site, Baltimore, Maryland, United States
Research Site, Stony Brook, New York, United States
Research Site, Columbus, Ohio, United States
Research Site, Ijuí, Brazil
Research Site, Londrina, Brazil
Research Site, São Caetano do Sul, Brazil
Research Site, Vitória, Brazil
Research Site, Anyang, China
Research Site, Beijing, China
Research Site, Bengbu, China
Research Site, Changchun, China
Research Site, Changsha, China
Research Site, Chengdu, China
Research Site, Chongqing, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06535607 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma →

← Back to all trials